An Anti-PD-L1 (A12) CAR-T with the ability to secrete anti-CD47 VHH (variable heavy domain of heavy chain antibodies or nanobodies) (A4), developed by Xie [87], represented a novel strategy for cancer treatment. This evidence concerns the gene CD274 and cancer.